Skip to main content

Table 4 Multivariate and univariate analyses of patient characteristics and T790M prevalence in patients with NSCLC harboring EGFR mutations, who had undergone rebiopsy after acquired resistance to EGFR-TKI (n = 61)

From: Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients

Patient characteristics Number T790M (%) P (Univariate) P (Multivariate)
Age    0.9292  
 ≥75 12 4 (33%)   
 <74 49 17 (35%)   
Sex    0.4904  
 Female 44 14 (32%)   
 Male 17 7 (41%)   
Smoking history    0.4904  
 Never 44 14 (32%)   
 Former/current 17 7 (41%)   
EGFR mutation status    0.1038  
 Exon19 deletion 37 9 (24%)   
 Exon21 L858R 19 9 (47%)   
 Other 5 3 (60%)   
Rebiopsy site    0.5813 0.9133
 Central nervous system 11 3 (27%)   
 Other 50 18 (36%)   
Rebiopsy sample    0.2017 0.5016
 Tissue 28 12 (43%)   
 Fluid 33 9 (27%)   
EGFR TKI    0.1208  
 Gefitinib 49 17 (35%)   
 Erlotinib 7 4 (57%)   
 2nd generation 5 0 (0%)   
Line of EGFR-TKI    0.4235  
 1st 39 12 (31%)   
 2nd or later 22 9 (41%)   
History of platinum doublet until rebiopsy 0.7021  
 Yes 34 11 (32%)   
 No 27 10 (37%)   
PFS with EGFR-TKI    0.4823  
 ≥10 months 34 13 (38%)   
 <10 months 27 8 (30%)   
Interval between RECIST PD and rebiopsy 0.2766  
 ≥4 months 29 12 (41%)   
 <4 months 32 9 (28%)   
Period of continuation of TKI beyond PD 0.0182 0.0417
 ≥30 days 20 11 (55%)   
 <30 days 41 10 (24%)   
  1. Abbreviations: EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, PFS progression free survival, PD progressive disease